


This application relates to quinazoline derivatives of formula (I),



pharmaceutical compositions comprising the compounds of formula (I), and the use of the compounds of formula (I) in the treatment or prevention of a viral infection, of a virus-induced disease, of cancer or of an allergy. In formula (I), R_1 is a C_{3-8} alkyl, optionally substituted by one or more substituents independently selected from fluorine, hydroxyl, amino, nitrile, ester, amide, C_{1-3} alkyl, or C_{1-3} alkoxy, the carbon of R_1 bonded to the amine in the 4-position of the quinazoline is in (R)-configuration, R_2 is hydrogen, deuterium, fluorine, chlorine, methyl, methoxy, cyclopropyl, trifluoromethyl, or carboxylic amide, wherein each of methyl, methoxy and cyclopropyl is optionally substituted by one or more substituents independently selected from fluorine and nitrile, R_3 is hydrogen or deuterium, R_4 is hydrogen, deuterium, fluorine, methyl, carboxylic ester, carboxylic amide, nitrile, cyclopropyl, C_{4-7} heterocycle, or 5-membered heteroaryl group, wherein each of methyl, cyclopropyl, C_{4-7} heterocycle and 5-membered heteroaryl group is optionally substituted by one or more substituents independently selected from fluorine, hydroxyl, or methyl, R_5 is hydrogen, deuterium, fluorine, chlorine, methyl, or methoxy, provided that at least one of R_2 , R_3 , R_4 and R_5 is not hydrogen.